

Metropolis Healthcare Ltd. recorded highest ever Revenue, EBITDA & PAT in FY22

Non-Covid revenue grew by 35% YoY to Rs. 1,036 crores

- Patient visits increased by 37% on YoY basis to 13.4 Mn in FY22
- No. of tests increased by 35% on YoY basis to 25.7 Mn in FY22
- Non-Covid Home Visits revenue increased by 23% YoY Rs. 98 Crs.

Mumbai, May 24, 2022: Metropolis Healthcare Ltd. (NSE: METROPOLIS | BSE: 542650) - a leading diagnostic service provider - announced its audited consolidated financial results today for the fourth quarter & financial year 2022.

FY22 Financial Highlights

Rs. 1,228 Crs.

Revenue
+23% YoY

Rs. 362 Crs.

EBITDA (Before CSR, ESOP &
One-time acquisition cost)
+20% YoY

29.4%

EBITDA Margin
(Before CSR, ESOP & One-
time acquisition cost)

“I am extremely pleased to share that inspite of all the challenges faced on account of covid led supply chain disruptions, we were able to record our highest ever Revenue, EBITDA & PAT in FY22. Strong performance was on the back of robust growth in the sustainable non-covid business.

During the year, we have made significant investments in digital, marketing, widening of leadership team and expansion of service network. These investments we make now will enable us to create a backbone for the next level of growth that we envisage in the business and help us safeguard our margins keeping in view the increased competitive intensity in coming times.

Going ahead, we will continue to build the brand on scientific basis, invest in core focus areas and on the acquisition front, drive the synergies at Hitech through quick & smooth integration.”

Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd.

ACCREDITATIONS FOR METROPOLIS

The Global Reference Laboratory of Metropolis holds accreditation from the College of American Pathologists (CAP) since 2005 which is the gold standard in accreditations in our industry, globally.

Our clinical laboratories hold one or more of CAP, NABL, KENAS, ILAC or APLAC accreditations.

(CAP: College of American Pathologists; NABL: National Accreditation Board for Testing and Calibration Laboratories; KENAS: Kenya Accreditation Service; ILAC: International Laboratory Accreditation Cooperation, APLAC: Asia Pacific Laboratory Accreditation Cooperation)

RECENT AWARDS AND ACCOLADES

Metropolis bagged the award for Innovation in Patient Centricity and Advocacy at the Patient First Summit 2022 from IHW (India Health & Wellness Council) for introducing the holistic comprehensive package 'PREGASCREEN'

Metropolis awarded with the 'Most Popular Diagnostic Laboratory Award' at the Healthcare Excellence Awards from Connect and Heal – CNH Care for demonstrating excellence in customer service based on user reviews.

Metropolis honoured with the 'Best of Bharat – Pride of India Brands' Award from Exchange4media.

Our MD Ms Ameera Shah honoured with the 'Outstanding Healthcare Leader of the Year' Award at the Women Achievers Award 2022, hosted by Abhyudaya Vatsalyam, acknowledging contribution and efforts in the healthcare sector.

Our CFO Mr. Rakesh Agarwal honoured with the FE CFO Year of the Award at the 5th edition of FE CFO Awards for his outstanding achievements, best practices and excellence.

Metropolis honoured with the Best Organizations for Women, 2022 by the Economic Times.

Our MD Ms Ameera Shah honoured with the 'Most Powerful Woman in Business Award by Business Today

Our MD Ms. Ameera Shah has won the Women Entrepreneur Award in Organizational Segment - Health & Wellness category at the Express Awards for Women Entrepreneurs (ExpressAWE), instituted by the Financial Express and FICCI FLO.

In INR Crs.	FY22	FY21	YoY
Revenue from Operations	1,228.3	998.0	+23%
EBIDTA (before CSR, ESOP & one-time acquisition cost)	361.6	301.3	+20%
EBIDTA margin (before CSR, ESOP & one-time acquisition cost)	29.4%	30.2%	
Reported Profit After Tax	214.7	183.3	+17%
Reported PAT Margin (%)	17.5%	18.4%	

About Metropolis: Metropolis Healthcare Ltd is a leading diagnostics company in India with a widespread presence across 20 states in India. Metropolis touches millions of lives each year by providing actionable health insights to patients and doctors. Metropolis offers a comprehensive range of 4000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. Metropolis' commitment to quality and accuracy in each test is reinforced by its consistent CAP proficiency score of more than 98% over the past decade, which places it amongst the top 1% laboratories worldwide for quality assurance. Metropolis philosophy rests on the pillars of technological superiority, a warm patient centric approach and reliable diagnostic reports. For more, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#).

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company: Metropolis Healthcare Ltd.

CIN -L73100MH2000PLC192798

Mr. Jeyasingh Balakrishnan – Head PR and Corporate Communications

jeyasingh.b@metropolisindia.com

www.metropolisindia.com

Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Shrenik Shah

shogun.jain@sgapl.net / shrenik.shah@sgapl.net